Emergence of new antibiotics for Bacteria

Resistance also increases the cost of health care with
lengthier stays in hospital and more intensive care
required. This one aspect has seen a step-forward in
relation to the unveiling of two new antibiotics. The
first of the new antibiotics is called Dalvance. This is
an intravenous drug that can treat skin and soft
tissue infections. The second drug is called
Oritavancin. Oritavancin is a lipoglycopeptide with
bactericidal activity against Gram-positive bacteria.
The drug was the subject of a clinical trial study led
by G. Ralph Corey of Duke University, and the
success was announced in the June 2014 edition of
the journal The New England Journal of Medicine.
Although the emergence of two new antibiotics is
promising, and will no doubt save many lives, their
emergence represents also highlights the lack of
progress in relation to other fields of medicine and
how far there is still to go in the battle against
bacterial 'superbugs'.
A review of two new classes of antibiotics to treat
skin infections forms the basis of a paper by Tim
Sandle for the journal Clinical Journal of Microbiology
and Pathology.
The reference is:
Sandle, T. (2014) Emergence of New Antibiotics. J
Micro Patho Volume 1, Issue 1: 001